Citadel Advisors’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.26M | Hold |
1,895,519
| – | – | ﹤0.01% | 2585 |
|
|
2025
Q1 | $3.85M | Sell |
1,895,519
-224,127
| -11% | -$455K | ﹤0.01% | 1976 |
|
|
2024
Q4 | $12.8M | Sell |
2,119,646
-20,982
| -1% | -$126K | ﹤0.01% | 1176 |
|
|
2024
Q3 | $15M | Buy |
2,140,628
+20,982
| +1% | +$147K | ﹤0.01% | 1020 |
|
|
2024
Q2 | $12.3M | Buy |
2,119,646
+439,619
| +26% | +$2.55M | ﹤0.01% | 1105 |
|
|
2024
Q1 | $12M | Buy |
1,680,027
+30,368
| +2% | +$217K | ﹤0.01% | 1187 |
|
|
2023
Q4 | $8.12M | Sell |
1,649,659
-798
| -0% | -$3.93K | ﹤0.01% | 1344 |
|
|
2023
Q3 | $15.8M | Buy |
1,650,457
+811
| +0% | +$7.75K | ﹤0.01% | 903 |
|
|
2023
Q2 | $21.4M | Buy |
1,649,646
+8,624
| +0.5% | +$112K | ﹤0.01% | 788 |
|
|
2023
Q1 | $20.1M | Buy |
1,641,022
+6,918
| +0.4% | +$84.9K | ﹤0.01% | 845 |
|
|
2022
Q4 | $18.2M | Buy |
+1,634,104
| New | +$18.2M | ﹤0.01% | 924 |
|